Dr. Natalie Nunez Gomez, Head of Global Medical Affairs, Psoriasis at UCB, discusses new, interim long-term results from the bimekizumab BE BRIGHT open-label extension study presented at the European Academy of Dermatology and Venereology (EADV) Congress, as well as additional findings from the Phase 3/3b clinical program for bimekizumab in psoriasis.
